(2R)-2-ethyl-4-propan-2-ylmorpholine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: (2R)-2-ethyl-4-propan-2-ylmorpholine
• 化学式: C₉H₁₉NO
• 分子量: 157.25
• InChiKey: GSXWLLVVULLWRN-SECBINFHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AS KINASE INHIBITOR AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES UTILISÉS EN TANT QU'INHIBITEURS DE KINASE ET LEURS UTILISATIONS
  申请人：INTEGRAL BIOSCIENCES PVT LTD

  公开号：WO2021019514A1

  公开（公告）日：2021-02-04

  The present disclosure relates generally to compounds useful in treatment of conditions associated with Checkpoint kinase (CHK), particularly CHK-1 enzymes. Specifically, the present invention discloses compound of formula (IA), which exhibits inhibitory activity against CHK-1 enzymes. Methods of treating conditions associated with excessive activity of CHK-1 enzymes with such compounds is disclosed. Uses thereof, pharmaceutical compositions, kits and method of synthesis also disclosed.

  本公开涉及一般用于治疗与检查点激酶（CHK）相关疾病的化合物，特别是CHK-1酶。具体地，本发明揭示了式（IA）的化合物，该化合物对CHK-1酶具有抑制活性。公开了使用这些化合物治疗与CHK-1酶过度活性相关的疾病的方法。还公开了这些化合物的用途、制药组合物、试剂盒和合成方法。
• TRIAZINE CARBOXAMIDES AS SODIUM CHANNEL BLOCKERS
  申请人：Purdue Pharma L.P.

  公开号：US20140249128A1

  公开（公告）日：2014-09-04

  The present disclosure provides substituted triazine carboxamides of Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A 1 , X, A 2 , E, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

  本公开提供了式I的替代三嗪羧酰胺化合物：和其药用可接受的盐和溶剂，其中A1、X、A2、E和Z的定义如规范中所述。本公开还涉及使用式I的化合物来治疗对钠通道阻滞有响应的疾病。本公开的化合物特别适用于治疗疼痛。
• PYRIMIDINES AS SODIUM CHANNEL BLOCKERS
  申请人：PURDUE PHARMA L.P.

  公开号：US20140303139A1

  公开（公告）日：2014-10-09

  The present disclosure provides substituted pyrimidine compounds of Formula (I), and the pharmaceutically acceptable salts, prodrugs, and solvates thereof, wherein A 1 , X, A 2 , W 1 , W 2 , E, Z, and R 4 are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula (I) to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

  本公开提供式（I）的取代嘧啶化合物，以及其药学上可接受的盐、前药和溶剂化物，其中A1、X、A2、W1、W2、E、Z和R4的定义如规范中所述。本公开还涉及使用式（I）的化合物治疗对钠通道阻滞响应的疾病。本公开的化合物特别适用于治疗疼痛。
• Human androgen receptor DNA-binding domain (DBD) compounds as therapeutics and methods for their use
  申请人：The University of British Columbia

  公开号：US10011573B2

  公开（公告）日：2018-07-03

  A compound having the structure of Formula I, wherein A is a substituted or unsubstituted aryl or heteroaryl group, D is a substituted or unsubstituted 5- or 6-membered heteroaryl or heterocyclyl group and E is a substituted or unsubstituted aryl, heteroaryl, cycloalkyl or heterocyclyl group. The compounds are used for the treatment of androgen modulated indications including cancer (prostate, breast, ovarian, endometrial or bladder cancer), hair loss, acne, hirsutism, ovarian cysts, polycystic ovary disease, precocious puberty and age related macular degeneration. The use of the compounds for the manufacture of a medicament for modulating AR activity, a method of treatment using such compounds and a pharmaceutical composition and a commercial package comprising said compounds are also described.

  具有式 I 结构的化合物，其中 A 是取代或未取代的芳基或杂芳基，D 是取代或未取代的 5 或 6 元杂芳基或杂环基，E 是取代或未取代的芳基、杂芳基、环烷基或杂环基。这些化合物可用于治疗雄激素调节适应症，包括癌症（前列腺癌、乳腺癌、卵巢癌、子宫内膜癌或膀胱癌）、脱发、痤疮、多毛症、卵巢囊肿、多囊卵巢病、性早熟和老年性黄斑变性。此外，还描述了这些化合物在制造调节 AR 活性的药物中的用途、使用这些化合物的治疗方法以及包含上述化合物的药物组合物和商业包装。
• Triazine carboxamides as sodium channel blockers
  申请人：Purdue Pharma L.P.

  公开号：US10000475B2

  公开（公告）日：2018-06-19

  The present disclosure provides substituted triazine carboxamides of Formula I: and the pharmaceutically acceptable salts and solvates thereof, wherein A1, X, A2, E, and Z are defined as set forth in the specification. The present disclosure is also directed to the use of compounds of Formula I to treat a disorder responsive to the blockade of sodium channels. Compounds of the present disclosure are especially useful for treating pain.

  本公开提供了式 I 的取代三嗪羧酰胺： 及其药学上可接受的盐和溶液，其中 A1、X、A2、E 和 Z 的定义如说明书所述。本公开还涉及使用式 I 的化合物治疗对阻断钠通道有反应的疾病。本公开的化合物尤其适用于治疗疼痛。